Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Viread

Viread 245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 130

HOS-110773 · Präparat HOS-093385

Medicinal product by Effects on drug levels Recommendation therapeutic areas Mean percent change in AUC, Cmax, concerning (dose in mg) Cmin co-administration with 245 mg tenofovir disoproxil ANTI-INFECTIVES Antiretrovirals Protease inhibitors Atazanavir/Ritonavir Atazanavir: No dose adjustment is (300 q.d./100 q.d.) AUC: ↓ 25% recommended. The increased Cmax: ↓ 28% exposure of tenofovir could Cmin: ↓ 26% potentiate Tenofovir: tenofovir-associated adverse AUC: ↑ 37% events, including renal Cmax: ↑ 34% disorders. Renal function Cmin: ↑ 29% should be closely monitored (see section 4.4). Lopinavir/Ritonavir Lopinavir/ritonavir: No dose adjustment is (400 b.i.d./100 b.i.d.) No significant effect on lopinavir/ritonavir recommended. The increased PK parameters. exposure of tenofovir could Tenofovir: potentiate AUC: ↑ 32% tenofovir-associated adverse Cmax: ↔ events, including renal Cmin: ↑ 51% disorders. Renal function should be closely monitored (see section 4.4). Darunavir/Ritonavir Darunavir: No dose adjustment is (300/100 b.i.d.) No significant effect on darunavir/ritonavir recommended. The increased PK parameters. exposure of tenofovir could Tenofovir: potentiate AUC: ↑ 22% tenofovir-associated adverse Cmin: ↑ 37% events, including renal disorders. Renal function should be closely monitored (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) darunavir (HOS-086181) ritonavir (HOS-084521)